Ethnicity and the diagnosis gap in liver disease: A population-based study

British Journal of General Practice

Volumn 64, Issue 628, 2014, Pages e694-e702

  Alazawi, William ^a   Mathur, Rohini ^a   Abeysekera, Kushala ^a   Hull, Sally ^a   Boomla, Kambiz ^a   Robson, John ^a   Foster, Graham R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ethnicity; Liver; Liver disease; NAFLD; Population

Indexed keywords

AMINOTRANSFERASE; AMIODARONE; AZATHIOPRINE; CARBAMAZEPINE; ETHAMBUTOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; METHOTREXATE; PHENYTOIN; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ALCOHOL LIVER DISEASE; ALPHA 1 ANTITRYPSIN DEFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; BANGLADESHI; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELTA AGENT HEPATITIS; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; ETHNIC GROUP; ETHNICITY; FEMALE; GENERAL PRACTICE; HEMOCHROMATOSIS; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER DISEASE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONALCOHOLIC FATTY LIVER; POPULATION BASED CASE CONTROL STUDY; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY MEDICAL CARE; PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR; SOUTH ASIAN; TOXIC HEPATITIS; WILSON DISEASE; ANCESTRY GROUP; ENGLAND; ETHNOLOGY; LIVER DISEASES; STATISTICS AND NUMERICAL DATA;

ADULT; BODY MASS INDEX; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ETHNIC GROUPS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER DISEASES; LIVER FUNCTION TESTS; LONDON; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 84908615650     PISSN: 09601643     EISSN: 14785242     Source Type: Journal    
DOI: 10.3399/bjgp14X682273     Document Type: Article

References (30)

1. Asrani SK, Larson JJ, Yawn B, et al. Underestimation of liver-related mortality in the United States. Gastroenterology 2013; 145: 375-82 e1-2.
2. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274-285.
4. Arnold DT, Bentham LM, Jacob RP, et al. Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort. BMC Fam Pract 2011; 12: 9.
5. McLernon DJ, Dillon JF, Sullivan FM, et al. The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI). PLoS One 2012; 7(12): e50965.
6. McLernon DJ, Donnan PT, Ryder S, et al. Health outcomes following liver function testing in primary care: a retrospective cohort study. Fam Pract 2009; 26(4): 251-259.
7. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 2001; 322(7281): 276-278.
8. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012; 56(1): 234-240.
9. Donnan PT, McLernon D, Dillon JF, et al. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). Health Technol Assess 2009; 13(25): iii-iv, ix-xi, 1-134.
10. Helsper C, van Essen G, Frijling BD, de Wit NJ. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care. Br J Gen Pract 2012; DOI: 10.3399/bjgp12X630115.
11. George K, Ryder S, Collier J, et al. BSG Guidelines. Management of Abnormal LFT in Asymptomatic Patients. British Society of Gastroenterology, 2013. http://www.bsg.org.uk/pdf-word-docs/ablft-draft05.doc (accessed 25 Sep 2014).
12. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42(1): 44-52.
13. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-1395.
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142(7): 1592-1609.
15. Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47(2): 239-244.
16. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140(1): 124-131.
17. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4): 917-23.
18. Bambha K, Belt P, Abraham M, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55(3): 769-780.
19. Ramaraj R, Chellappa P. Cardiovascular risk in South Asians. Postgrad Med J 2008; 84(996): 518-523.
20. National Institute for Health and Care Excellence. Assessing body mass index and waist circumference thresholds for intervening to prevent ill health and premature death among adults from black, Asian and other minority ethnic groups in the UK. NICE guidelines [PH46] Published date: July 2013. http://www.nice.org.uk/guidance/ph46 (accessed 7 Oct 2014).
21. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342(17): 1266-1271.
22. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23(5): 1025-1029.
23. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26(4): 401-412.
24. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137(1): 1-10.
25. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328(7446): 983.
26. Lilford RJ, Bentham L, Girling A, et al. Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. Health Technol Assess 2013; 17(28): i-xiv, 1-307.
27. Uddin G, Shoeb D, Solaiman S, et al. Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat 2010; 17(5): 327-335.
28. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126(2): 137-145.
29. Grace C, Begum R, Subhani S, et al. Prevention of type 2 diabetes in British Bangladeshis: qualitative study of community, religious, and professional perspectives. BMJ 2008; 337: a1931.
30. Greenhalgh T, Helman C, Chowdhury AM. Health beliefs and folk models of diabetes in British Bangladeshis: a qualitative study. BMJ 1998; 316(7136): 978-983.